$5.55M Metformin Settlements Partially Resolve Class Action Litigation Over Contaminated Diabetes Meds

New to ClassAction.org? Read our Newswire Disclaimer

Teva, Granules and Heritage have reached class action settlements to partially resolve multidistrict litigation (MDL) that alleged the pharmaceutical companies falsely advertised generic metformin-containing drugs as the same as or equivalent to Glucophage and/or Glucophage XR, when the diabetes meds were in fact contaminated with N-nitrosodimethylamine (NDMA).

Get class action lawsuit and class action settlement news sent to your inbox – sign up for ClassAction.org’s free weekly newsletter.

The Metformin class action settlements with Teva Pharmaceuticals USA, Inc., Actavis Pharma, Inc., and Actavis LLC (collectively “Teva”) and Granules USA, Inc., Granules Pharmaceuticals, Inc., and Heritage Pharmaceuticals, doing business as Avet Pharmaceuticals, Inc. (collectively “Granules and Heritage”), received preliminary approval from the court on May 4, 2026.

The $3 million Teva MDL settlement covers all individuals or entities in the United States and its territories and possessions who paid any amount of money for a metformin-containing drug intended for personal/household use that was manufactured, distributed or sold by Teva from July 20, 2015 through June 2, 2020.

The $2.55 million Granules and Heritage MDL settlement covers all individuals and entities in the United States and its territories and possessions who paid any amount of money for a metformin-containing drug intended for personal/household use that was manufactured, distributed or sold by Granules or Heritage from July 20, 2015 through June 2, 2020.

The court-approved website for the Metformin settlements, which includes information about both deals, can be found at InReMetforminSettlement.com.

Class members who submit a timely, valid claim form can receive a pro rata cash payment from the Metformin settlement fund.

The final amount of this payout will depend on the number of generic metformin-containing drugs a class member purchased, how much they paid, and the total number of valid claims submitted.

To submit a Metformin NDMA settlement claim form online, class members can head to this page and select whether they are submitting a claim as an individual consumer or a third-party payor. Alternatively, class members can download a PDF claim form from the same page to print, complete, and return by mail to the settlement administrator.

All Teva or Granules and Heritage settlement claim forms must be submitted online or postmarked no later than July 10, 2026.

The court will determine whether to grant the settlements final approval following a hearing on August 12, 2026. Compensation will begin to be distributed to class members only after final approval has been granted and any appeals have been resolved.

The Metformin class action lawsuit remains ongoing against the remaining defendants and alleges that a laundry list of pharmaceutical companies falsely advertised their generic drugs containing metformin as the same as or equivalent to Glucophage and/or Glucophage XR, brand-name prescription medications used to treat type 2 diabetes.

However, the class action lawsuits, which were eventually consolidated into an MDL, alleged that the drugs were contaminated with the carcinogen NDMA and did not comply with metformin standards set by the Food and Drug Administration. The case alleged that consumers and businesses ultimately paid more for the drugs than they would have absent the defendants’ allegedly false advertising.

Did you know that some class action settlements require no proof to submit a claim? Check out the latest open class action settlements.